Baker Bros. Advisors LP Aligos Therapeutics, Inc. Transaction History

Baker Bros. Advisors LP

  • $9.02 Billion
  • Q4 2024

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021
BUY
$14.57 - $17.72 $6.8 Million - $8.26 Million
466,400 Added 28.97%
2,076,400 $32.2 Million
Q4 2020

Feb 16, 2021
BUY
$13.2 - $32.74 $21.3 Million - $52.7 Million
1,610,000 New
1,610,000 $44.5 Million

Others Institutions Holding ALGS

# of Institutions
2
Shares Held
227K
Call Options Held
0
Put Options Held
0
View Full List

About Aligos Therapeutics, Inc.

ALGS Quotes by TradingView
  • Ticker ALGS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,717,000
  • Market Cap $514M
  • Description
  • Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...
More about ALGS
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email